Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
NASDAQ
$78.08
▼ DOWN 2.16% (-1.72)

KEY STATISTICS

Market Cap$5.95 B
52w High$82.94
52w Low$33.45
Dividend Yield—
Frequency—
P/E86.76
Volume427.25K
Shares Out.76.21M

COMPANY

LEADERSHIP

Sanj K. Patel
CHIEF EXECUTIVE
Sanj K. Patel

COMPENSATION 2026

Salary$943,129
Stock Awards$0
Incentive Plan Pay$1,284,065
All Other Comp.$14,000
Total$10,782,661

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 24, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
366

PRICE TARGET

Target High$99.00
Target Low$71.00
Target Median$90.00
Target Consensus$86.40

UPCOMING EARNINGS

DateOct 27, 2026
DayTuesday
Rev. Est.$259.65M
OCT
27
TUE

PRICE

$78.08 ▼ DOWN 2.16% (−$1.72)
$78.00$78.75$79.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM78.08

About Kiniksa Pharmaceuticals International, plc

https://www.kiniksa.com ↗

Kiniksa Pharmaceuticals, Ltd. is a Bermuda-based biopharmaceutical company developing therapies for unmet medical needs, with candidates like ARCALYST, Mavrilimumab, Vixarelimab, and KPL-404 targeting inflammatory and immune-related diseases.

INDUSTRY

Medical - Pharmaceuticals

A PRODUCT KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC IS KNOWN FOR

ARCALYST® (rilonacept)
ARCALYST® (rilonacept)

ARCALYST is the first FDA-approved weekly injectable therapy for recurrent pericarditis, blocking IL-1α and IL-1β to reduce inflammation, and is Kiniksa's leading and most commercially significant product.

COMPETITORS

COMPETITOR
ABBV COMPARE
AMGN COMPARE
CRDL COMPARE
NVS COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$180.85M $202.13M ▲$214.27M ▲$243.6M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
142
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.3M
XSU.TO
0.10% · 1.1M
DFAS
0.08% · 150.6K
XS5G.L
0.12% · 140.3K
PSC
0.28% · 96.0K
R2US.L
0.11% · 80.9K
AVSC
0.14% · 54.5K
JSML
0.82% · 39.4K
FFTY
3.51% · 33.6K
BBP
1.89% · 28.2K
PRFZ
0.06% · 20.3K
RSSL
0.11% · 20.2K
FFSM
0.10% · 20.0K
AFSM
0.70% · 11.4K
SMCP
8.73% · 11.2K
HY
HYP
1.08% · 9.7K
EES
0.10% · 9.2K
GSSC
0.06% · 8.7K
EH
EHLS
0.85% · 6.3K
HELX
0.75% · 3.1K
FORH
0.99% · 2.5K
URTY
0.04% · 1.7K
PQ
PQSG
0.16% · 1.6K
STXK
0.14% · 1.5K
TILT
0.00% · 1.2K
SMCF
1.09% · 445

INSTITUTIONAL OWNERSHIP

SHARES OWNED
55.21%
HOLDERS
351
TOP 12 OF 351 · RANKED BY POSITION SIZE
Rockefeller Capital Management L.P.
7.2M sh · $7.15M
Fmr LLC
7.0M sh · $445.82M
Blackrock Inc.
4.6M sh · $85.72M
Rubric Capital Management LP
4.0M sh · $155.32M
Pictet Asset Management Ltd
3.3M sh · $46.45M
Vanguard Group Inc
3.1M sh · $128.41M
Baker Bros. Advisors LP
2.8M sh · $181.28M
Blackrock, Inc.
2.7M sh · $175.2M
Tang Capital Management LLC
2.3M sh · $90.42M
Fairmount Funds Management LLC
1.8M sh · $68.84M
Acadian Asset Management LLC
1.7M sh · $70.63M
Pictet Asset Management SA
1.5M sh · $21.36M

RATINGS SNAPSHOT

Overall rating: B

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity4
Return On Assets5
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score3

INSIDER TRADES

★
DIRECTOR
Quart Barry D
Sale · 2.6K shares
2026-08-19
★
DIRECTOR
Levy Richard S
Purchase · 403 shares
2026-08-01
★
DIRECTOR
Levy Richard S
Purchase · 403 shares
2026-08-01
★
DIRECTOR
Cole G Bradley
Sale · 4.5K shares
2026-07-29

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 2
OUTPERFORM 1
7 GRADES IN THE LAST 12 MONTHS
Goldman Sachs BUY Citigroup BUY Canaccord Genuity BUY JP Morgan OVERWEIGHT Wedbush OUTPERFORM Wells Fargo OVERWEIGHT Jefferies BUY

SECTORS PEERS

PEERPRICE
SRRK$57.80COMPARE
ADPT$25.19COMPARE
IDYA$40.11COMPARE
VCYT$43.34COMPARE
ZLAB$26.08COMPARE
MLYS$25.60COMPARE